Structure-guided optimization of a novel class of ASK1 inhibitors with increased sp


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 19 05 2020
revised: 06 07 2020
accepted: 07 07 2020
entrez: 3 8 2020
pubmed: 3 8 2020
medline: 9 6 2021
Statut: ppublish

Résumé

Apoptosis Signal-Regulating Kinase-1 (ASK1) is a known member of the Mitogen-Activated Protein Kinase Kinase Kinase (MAP3K) family and upon stimulation will activate the p38- and JNK-pathways leading to cardiac apoptosis, fibrosis, and hypertrophy. Using Structure-Based Drug Design (SBDD) in parallel with deconstruction of a published compound, a novel series of ASK1 inhibitors was optimized, which incorporated a saturated heterocycle proximal to the hinge-binding motif. This yielded a unique chemical series with excellent selectivity across the broader kinome, and desirable drug-like properties. The lead compound (10) is highly soluble and permeable, and exhibits a cellular EC

Identifiants

pubmed: 32738982
pii: S0960-894X(20)30516-3
doi: 10.1016/j.bmcl.2020.127405
pii:
doi:

Substances chimiques

Imidazoles 0
Protein Kinase Inhibitors 0
imidazole 7GBN705NH1
MAP Kinase Kinase Kinase 5 EC 2.7.11.25
MAP3K5 protein, human EC 2.7.11.25

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

127405

Informations de copyright

Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Simone V Bigi-Botterill (SV)

Medicinal Chemistry & In Vitro Pharmacology, Gastroenterology Drug Discovery Unit, Takeda Research in California, 9625 Towne Centre Drive, San Diego, CA 92121, United States. Electronic address: simone.bigi@takeda.com.

Anthony Ivetac (A)

Mirati Therapeutics, 9393 Towne Centre Drive #200, San Diego, CA 92121, United States.

Erica L Bradshaw (EL)

Quantitative Translational Sciences, Takeda Research in California, 9625 Towne Centre Drive, San Diego, CA 92121, United States.

Derek Cole (D)

Medicinal Chemistry & In Vitro Pharmacology, Gastroenterology Drug Discovery Unit, Takeda Research in California, 9625 Towne Centre Drive, San Diego, CA 92121, United States.

Douglas R Dougan (DR)

Structural Biology & Biophysics, Gastroenterology Drug Discovery Unit, Takeda Research in California, 9625 Towne Centre Drive, San Diego, CA 92121, United States.

Jacques Ermolieff (J)

Medicinal Chemistry & In Vitro Pharmacology, Gastroenterology Drug Discovery Unit, Takeda Research in California, 9625 Towne Centre Drive, San Diego, CA 92121, United States.

Petro Halkowycz (P)

Medicinal Chemistry & In Vitro Pharmacology, Gastroenterology Drug Discovery Unit, Takeda Research in California, 9625 Towne Centre Drive, San Diego, CA 92121, United States.

Ben Johnson (B)

Medicinal Chemistry, Neuroscience Drug Discovery Unit, Takeda Research in California, 9625 Towne Centre Drive, San Diego, CA 92121, United States.

Christopher McBride (C)

858 Therapeutics, 4757 Nexus Center Drive #150, San Diego, CA 92121, United States.

Jason Pickens (J)

Medicinal Chemistry & In Vitro Pharmacology, Gastroenterology Drug Discovery Unit, Takeda Research in California, 9625 Towne Centre Drive, San Diego, CA 92121, United States.

Mark Sabat (M)

Medicinal Chemistry & In Vitro Pharmacology, Gastroenterology Drug Discovery Unit, Takeda Research in California, 9625 Towne Centre Drive, San Diego, CA 92121, United States.

Steven Swann (S)

Chemistry & Design, Silicon Therapeutics, 451 D Street #205, Boston, MA 02210, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH